Cholinergic neurotransmission depends upon the regulated release of acetylcholine. This requires the loading of acetylcholine into synaptic vesicles by the vesicular acetylcholine transporter (VAChT). Here, we identify point mutants in Caenorhabditis elegans that map to highly conserved regions of the VAChT gene of Caenorhabditis elegans (CeVAChT) (unc-17) and exhibit behavioral phenotypes consistent with a reduction in vesicular transport activity and neurosecretion. Several of these mutants express normal amounts of VAChT protein and exhibit appropriate targeting of VAChT to synaptic vesicles. By site-directed mutagenesis, we have replaced the conserved amino acid residues found in human VAChT with the mutated residue in CeVAChT and stably expressed these cDNAs in PC-12 cells. These mutants display selective defects in initial acetylcholine transport velocity (K m ), with values ranging from 2-to 8-fold lower than that of the wild-type. One of these mutants has lost its specific interaction with vesamicol, a selective inhibitor of VAChT, and displays vesamicolinsensitive uptake of acetylcholine. The relative order of behavioral severity of the CeVAChT point mutants is identical to the order of reduced affinity of VAChT for acetylcholine in vitro. This indicates that specific structural changes in VAChT translate into specific alterations in the intrinsic parameters of transport and in the storage and synaptic release of acetylcholine in vivo.
Acetylcholine is synthesized by choline acetyltransferase in the cytoplasm of cholinergic nerve terminals and transported into synaptic vesicles by a vesicular acetylcholine transporter (VAChT). 1 Genetic and behavioral analyses of various point mutants in Caenorhabditis elegans have revealed that the genes encoding both cholinergic proteins map to the same genetic locus and that their co-expression is required for acetylcholine release (1) (2) (3) (4) . Mutations in the gene encoding choline acetyltransferase (cha-1) and in the gene encoding VAChT (unc-17) lead to similar behavioral defects, and both mutations protect against the toxicity of organophosphorus compounds such as aldicarb. Aldicarb inhibits the degradative enzyme acetylcholinesterase, allowing the toxic accumulation of acetylcholine in the synaptic cleft. These mutations confer resistance to esterase inhibition by reducing the efficiency of acetylcholine neurosecretion. One difference in phenotype between mutants in the two genes is that choline acetyltransferase mutants have decreased levels of acetylcholine within cholinergic nerve terminals, whereas VAChT mutants have increased levels of acetylcholine within cholinergic nerve terminals (5, 6) . However, the increased acetylcholine level in CeVAChT mutants is not available for synaptic release due to specific defects in the level of expression or in the intrinsic activity of VAChT.
Vesicular acetylcholine transport is essential for cholinergic neurotransmission because homozygous VAChT knockout mutants in C. elegans and in Drosophila melanogaster do not live for more than a few days (3, 7) . Genetic manipulation of the level of VAChT expression can influence acetylcholine synaptic release. In Drosophila, VAChT heterozygotes show decreased cholinergic transmission with high frequency stimulation (7) . Conversely, overexpression of VAChT in Xenopus embryos increases the magnitude of postsynaptic currents at developing neuromuscular junctions by 2-to 3-fold (8) . This is consistent with the increase in vesicular packaging of acetylcholine observed in vitro after overexpression of VAChT in cholinergic cells (9, 10) . Thus, the level of VAChT expression may alter the rate and extent of synaptic vesicle accumulation of acetylcholine.
Relatively little is known regarding the role of the intrinsic activity of VAChT on the vesicular accumulation and synaptic release of acetylcholine. Inhibition of acetylcholine transport into synaptic vesicles by vesamicol, which selectively binds to VAChT, blocks quantal acetylcholine secretion in vivo (9 -15) . Sequence conservation of the aspartic acid residues within the putative hydrophobic transmembrane domains (TMDs) of VAChT from several species suggests functional importance in intrinsic activity. Some of these aspartate residues have been shown to be critical for the activity of VAChT (16, 17) . When an aspartate residue is changed in TMD IV (D193N) or in TMD X (D398N), overexpression of rat VAChT in Xenopus neuromuscular junctions no longer leads to an increase in quantal acetylcholine secretion (8) . Interestingly, overexpression of D398N appears to result in a dominant negative effect that reduces endogenous quantal acetylcholine secretion (8) . In vesicles isolated from PC-12 cells, the D398N mutation completely abol-ishes acetylcholine transport and vesamicol binding, whereas the D193N mutant transports acetylcholine at the same rate as wild-type transporter (16) .
VAChT is part of a gene family that includes the vesicular monoamine transporters VMAT1 and VMAT2 (18) . The functional activity of vacht relies upon the proton electrochemical gradient established by a vacuolar-type H ϩ -ATPase (9, 10, 19) . A chimeric VAChT molecule in which TMD I is replaced by TMD I of VMAT2 shows a reduced affinity for acetylcholine but retains vesamicol binding (20) . This suggests that TMD I of VAChT, like the TMD I of VMAT, is involved in substrate translocation (21) . However, the ammonium headgroup of acetylcholine may interact with Asp-425 in TMD XI instead of Asp-46 in TMD I, which is hypothesized to interact with the primary amino group of monoamines (16, 21) . The roles of conserved basic amino acid residues within the TMDs of VAChT have also been examined by mutagenesis. A putative charge-pair interaction between His-338 in TMD VIII and Asp-398 in TMD X has been proposed to anchor the TMD helices together (17) . The presence of a salt bridge in membranespanning regions of VAChT may be important in facilitating the conformational changes associated with H ϩ /acetylcholine antiport. In VMATs, the negative charge in TMD X is hypothesized to play a direct role in H ϩ translocation (22) . A conserved lysine residue in TMD II (Lys-131) is also critical for VMAT and VAChT function (17, 23) . Thus, Lys-131, His-338, and Asp-398 play important roles in the mechanism of action of VAChT, possibly as components of a H ϩ relay system, as described for VMATs and the lactose permease, a H ϩ -symporter that belongs to the same sequence-defined superfamily (22) (23) (24) (25) (26) (27) .
In the present report, we have analyzed 12 different nonlethal point mutations in the CeVAChT in an effort to identify additional domains of VAChT involved in acetylcholine translocation. Several mutations are at residues that are conserved in vertebrate VAChTs and are associated with normal levels of VAChT protein in cholinergic nerve endings. These mutant proteins also exhibit appropriate targeting to synaptic vesicles. The analysis of the acetylcholine transport and vesamicol binding properties of hVAChT constructs containing these mutations expressed in a heterologous system in vitro provides new information regarding the location of the acetylcholine transport recognition site in VAChT. Furthermore, the combination of a genetic approach in C. elegans and biochemistry in vitro establishes a direct relationship between the intrinsic parameters of vesicular acetylcholine transport in vitro and the storage and synaptic release of acetylcholine in vivo.
EXPERIMENTAL PROCEDURES
Culture Conditions and Strains-C. elegans strains were grown on solid medium as described previously (3, 28) .
The unc-17 alleles md65 and md69 were ethyl methane sulfonateinduced and identified by noncomplementation with pre-existing unc-17 mutations (3); md334, md414, and md1107 were isolated as spontaneous mutants resistant to the acetylcholinesterase inhibitor aldicarb (6, 29) . Alleles with p designations were ethyl methane sulfonate-induced (in Richard Russell's laboratory) and isolated by resistance to aldicarb (30) . The unc-17 alleles with e allele designations were isolated at the Medical Research Council (Cambridge, United Kingdom) and generously provided by Jonathan Hodgkin. All mutants were outcrossed to wild-type (N2 Bristol) at least four times.
Sequence of Mutant Alleles-The sequence alterations associated with the e245 and p1160 alleles have been published previously (3) . Sequence analysis of the remaining unc-17 mutations involved amplification of specific 1-2-kilobase unc-17 genomic regions using direct "single-worm polymerase chain reaction" from individual mutant animals (31) followed by sequencing of the amplified genomic DNA with internal primers. Oligonucleotide primers were synthesized by the Molecular Biology Resource Facility of the University of Oklahoma Health Sciences Center.
Immunostaining-Nematodes were prepared with a variation of the "freeze-crack" method and stained with an anti-CeVAChT mouse monoclonal antibody (Mab 1403) as described previously (32) (33) (34) . Phenotype Analysis-All behavioral measurements were performed at 20°C. The procedures for observing and quantifying pharyngeal pumping and body thrashing in liquid have been described previously (29, 35) . Values are normalized to N2 ϭ 100% and are presented Ϯ S.D. (10 -50 individuals were counted for each allele). An approximate measure of growth rate at 20°C was determined by a "plate-clearing" method (36) . Twenty L1 animals were placed on a streak plate and examined once or twice a day, until all the food was consumed. A total of one to four plates were analyzed per allele. The growth rate for each strain is defined as the inverse of the number of days to consume all the food, and the "relative growth rate" is calculated as ratio of the mutant growth rate to the wild-type rate.
Construction of hVAChT Mutants-Site-directed mutagenesis was performed using a 640-base pair Sse8387I/SalI fragment of hVAChT (contains coding sequences that include TMD IV through TMD X) subcloned into pUC18 using the method of Deng and Nickoloff (37) . The Escherichia coli BMH 71-18 mutS bacterial strain and buffers were provided with the Transformer Site-directed Mutagenesis Kit (CLONTECH). Transformants were screened by cDNA doublestranded sequencing using the Sequenase kit (United States Biochemical). The mutated hVAChT fragment was then reintroduced into the wild-type hVAChT cDNA and subcloned into pRc/CMV at HindIII/NotI for transfection into PC-12 cells.
Cell Transfections and Selection of Stable PC-12 Cell Lines-Rat PC-12 cells were maintained at 37°C in an atmosphere of 95% air, 5% CO 2 in Dulbecco's modified Eagle's medium containing 7% fetal bovine serum, 7% heat-inactivated horse serum, 100 units/ml penicillin, 100 mg/ml streptomycin, and 4 mM glutamine. PC-12 cells were transfected with the hVAChT constructs using Lipofectin (10 g/ml; Life Technologies, Inc.), and stable transformants were selected with 0.5 mg/ml Geneticin (G418; Life Technologies, Inc.). Geneticin-resistant colonies were picked and screened by immunocytochemistry as described previously (38) . Cells were fixed for 2 h in 10% formalin/phosphate-buffered saline and incubated with species-specific hVAChT antipeptide rabbit polyclonal antisera (39) at a final dilution of 1:2000 in phosphatebuffered saline, 0.1% Triton, and 3% normal goat serum. Primary antibodies were visualized using VectaStain Kit (Vector Laboratories Inc.).
Membrane Preparation and Vesicular Acetylcholine Transport Assay-Control PC-12 cells and the lines expressing hVAChT and the hVAChT mutants were grown to confluence in a T175 flask, treated with 6 mM sodium butyrate, and incubated for an additional 36 h. This treatment increases expression from viral promoters (40) and does not affect the biochemical parameters of acetylcholine transport or targeting of VAChT to cholinergic vesicles in PC-12 cells. Transient transfections were also performed in CV-1 fibroblasts by the T7-vaccinia hybrid system as described previously (11) . The cells were rinsed with phosphate-buffered saline, collected in phosphate-buffered saline containing 10 mM EDTA (pH 7.4), and centrifuged at 800 ϫ g for 5 min. To prepare postnuclear supernatants, the cell pellets were resuspended and homogenized in a ball-bearing device (20 strokes, 11 m clearance) in ice-cold buffer containing 80 mM potassium tartrate, 20 mM HEPES, 0.5 mM EGTA, and 1 mM ascorbic acid, adjusted to pH 7.0 with KOH, and supplemented with a protease inhibitor mixture (0.2 mM phenylmethylsulfonyl fluoride, 2 mg/ml leupeptin, 2 mg/ml aprotinin, and 2 mg/ml pepstatin) and 50 M esterase inhibitor echothiophate (Wyeth Ayerst Laboratories). The nuclei and unbroken cells were removed by centrifugation at 2000 ϫ g for 10 min. The protein content in the supernatant was measured using the Bradford assay (41). ]acetylcholine uptake assay, aliquots (100 l) of postnuclear homogenates containing 200 g of protein were preincubated at 37°C for 5 min in the presence and absence of L-vesamicol (Research Biochemicals Inc.) as described previously (42) . After preincubation, 100 l of uptake buffer containing 110 mM potassium tartrate, 20 mM HEPES, 1 mM ascorbic acid, 50 M echothiophate, and 10 mM Mg 2ϩ -ATP (neutralized with KOH to pH 7.4) and various concentrations of tritiated (0.4 mM; 55.2 mCi/mmol; PerkinElmer Life Sciences) and unlabeled acetylcholine were added. The final concentration of Mg 2ϩ -ATP was 5 mM. Uptake was terminated after 10 min by placing tubes in an ice water bath, filtering through GF/C glass fiber filters (Whatman), and washing with 5 ml of ice-cold uptake buffer. Homogenates from control PC-12 cells and human VAChT-expressing PC-12 cells were always analyzed in parallel to assess the specific acetylcholine uptake derived from endogenous PC-12 VAChT, which is generally less than 2-fold more than that seen at 4°C or in the presence of 2 M vesamicol.
Vesamicol Binding Assay-Aliquots of postnuclear supernatant (30 g of protein in 50 l) were mixed with binding buffer containing 110 mM potassium tartrate and 20 mM HEPES at pH 7.4 (50 l) and various concentrations of [ 3 H]vesamicol (31 Ci/mmol; PerkinElmer Life Sciences). For acetylcholine displacement of [ 3 H]vesamicol binding, the organelles in the postnuclear homogenates were first lysed by dilution (1:10) in ice-cold 20 mM HEPES containing peptidase inhibitors and centrifugation at 100,000 ϫ g for 1 h. The pellets were resuspended in binding buffer, and [ 3 H]vesamicol (final concentration, 20 nM) and various amounts of unlabeled acetylcholine were added. After a 30-min incubation at 20°C, the reactions were stopped by vacuum filtration through GF/C glass fiber filters (Whatman) presoaked in 0.5% polyethyleneimine, followed by a 5-ml wash with ice-cold buffer containing 110 mM potassium tartrate and 20 mM HEPES, pH 7.4. Radioactivity bound to the filters was solubilized in 1 ml of 1% SDS and measured by scintillation counting in 10 ml of EcoScint (National Diagnostics). Nonspecific binding was determined in the presence of 30 M L-vesamicol and subtracted from the total binding.
Synaptic Vesicle Targeting-For equilibrium density fractionation, postnuclear supernatants (about 1 mg of protein) were loaded onto a continuous 4.4 ml of 0.6 -1.6 M (20 -46%) sucrose gradient buffered with 20 mM HEPES, pH 7, and 5 mM EGTA for sedimentation at 46,000 rpm at 4°C for 3 h in a SW55 rotor. For glycerol velocity fractionation, we used a modification of the method described by Kelly and co-workers (40) . Briefly, the postnuclear supernatant was centrifuged at 10,000 ϫ g for 10 min, and the resulting supernatant (about 1 mg of protein) was loaded onto a 4.4-ml 5-25% glycerol gradient prepared in homogenization buffer for a 45-min centrifugation at 55,000 rpm in a SW55 rotor. For both gradients, a first fraction equivalent to the volume loaded and successive 350-l fractions were collected from the top. The linearity of the gradients was verified by refractometry.
Western Blot Analysis-Equivalent amounts of protein from the postnuclear supernatants of the stable PC-12 lines expressing hVAChT and the hVAChT mutants or equal volumes of each gradient fraction were processed for Western blot analysis. High-speed pellets were prepared from diluted gradient fractions. Sucrose gradient fractions were brought to 320 mM sucrose with 20 mM HEPES, pH 7, whereas glycerol gradient fractions were diluted 5-fold in the same buffer. Both were spun for 1 h at 45,000 rpm at 4°C in a Ti50.4 rotor. Pellets were solubilized in sample buffer containing 62 mM Tris-HCl, pH 6.8, 1 mM EDTA, 10% glycerol, 5% SDS, and 50 mM dithiothreitol. Membrane proteins were separated on 8% polyacrylamide gels and electrotransferred onto nitrocellulose (Hybond-ECL; Amersham Pharmacia Biotech). Chromogranin B and synaptophysin (p38) were detected in aliquots taken directly from gradient fractions and dissolved in sample buffer. After a 1-h preincubation in TBS (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.1% Tween 20) containing 5% nonfat dry milk, the blots were incubated for 2 h at room temperature with affinity-purified anti-hVAChT at 1 mg/ml (38), anti-chromogranin B at 1:1000 (a gift from R. Fischer-Colbrie, Innsbruck, Austria), or anti-p38 at 1:5000 (Sigma) in TBS-1% bovine serum albumin. Bound primary antibodies were visualized using a monoclonal anti-rabbit antibody or a polyclonal anti-mouse antibody, both of which were coupled to peroxidase (Sigma), and an enhanced chemiluminescence system (ECL; Amersham Pharmacia Biotech).
RESULTS

Several Sequence Alterations Occur at Conserved Residues in
VAChT-The sequence alterations of 19 independent unc-17 point mutants, corresponding to 12 distinct amino acid substitutions, are presented in Fig. 1 . These fall predominantly into three categories: (a) those at amino acids that are conserved among VMATs and VAChT, (b) those found only in VAChTs, and (c) those unique to CeVAChT. Only one mutation (CeR60W) was found at a residue unique to CeVAChT; it was localized in the first intralumenal loop. Six mutants (CeE98K, CeG103R, CeG103E, CeG342E, CeG347R, and CeY400N) had sequence alterations at amino acid residues that are conserved in VMATs and VAChT. Five of these mutations lie in predicted TMDs (TMDs II, IX, and XI), whereas one (CeE98K) is in the luminal loop between TMD I and TMD II. The CeG103R/E, CeG342E, and CeG347R mutations introduce a charged residue into the putative TMDs. Four CeVAChT mutations (CeA206V, CeC230F, CeT292del, and CeC370Y) were at amino acids that are relatively conserved in Torpedo, rat, and human VAChT but are not conserved in VMATs. Three of these VAChT-specific residues introduce a larger and more hydrophobic amino acid residue in predicted TMDs (TMDs V, VI, and X), and one (CeT292del) was found in the luminal loop between TMD VII and VIII. One mutation (CeS211F) is at an amino acid conserved in VMATs, whereas this residue in vertebrate VAChTs is glycine (G233).
C. elegans mutants were screened for normal levels of CeVAChT immunoreactivity. Mutations at two locations (CeG342E and CeG347R) led to lower levels of CeVAChT protein. These mutations altered residues conserved in VAChTs and VMATs, and they probably destabilized the VAChT protein. All of the VAChT-specific mutations as well as CeS211F express relatively normal amounts of protein that is appropriately targeted to cholinergic endings (Fig. 2) .
Behavioral Phenotypes of unc-17 Mutants-We measured three phenotypes of the unc-17 mutants (Fig. 3) . The rates of pharyngeal pumping and thrashing in liquid are measures of neuromuscular function in the pharynx and the body muscles, respectively. The "plate clearing" assay is affected by both the generation time and the fecundity of the mutants. By each of these criteria, e327 (CeS211F), e795 (CeA206V), and p1160 (CeC230F) form a graded series of increasing severity, whereas md414 (CeC370Y) homozygotes have approximately normal growth and only moderately impaired neuromuscular function. For comparison, the properties of the unc-17 reference allele e245 (CeG347R) are also presented in Fig. 3 . However, because e245 has lower levels of VAChT immunoreactivity in vivo (Fig.  2) , it is difficult to compare the e245 phenotypic data directly to the other mutants.
VAChT-specific Mutant Proteins Are Stable and Retain Targeting to Synaptic Vesicles-We have further examined the effect of these mutations on VAChT function in a heterologous system that has been used to study the vesicular trafficking and transport function of mammalian VAChT (9, 38). By site- directed mutagenesis, we have replaced VAChT-specific residues in human VAChT (A228, S252, and C391) and G233 that correspond to the mutated residues found in three putative TMDs (TMDs V, VI, and X) of the CeVAChT protein (CeA206V, CeC230F, CeC370Y, and CeS211F) and stably expressed these cDNAs in neuroendocrine PC-12 cells.
PC-12 cells stably expressing wild-type or mutant hVAChT constructs show similar levels of immunoreactivity of Western blots. Western blot analysis of subcellular fractions from sucrose equilibrium density gradients of homogenates revealed that hVAChT immunoreactivity was present in light fractions that contain p38, a marker of small synaptic vesicles (Fig. 4) . Likewise, centrifugation through glycerol, which separates synaptic vesicles from endosomal compartments, revealed a co-localization of hVAChT immunoreactivity with p38. These data indicate that the mutant VAChT proteins are stable and appropriately targeted to cholinergic secretory organelles.
VAChT-specific Mutants Alter Intrinsic Parameters of Transport-The intrinsic acetylcholine transport activity, the binding of vesamicol, and the ability of acetylcholine to displace vesamicol binding to the VAChT-specific mutants were examined in synaptic vesicle preparations from stable PC-12 cell lines. Acetylcholine recognition was evaluated by examining initial velocity kinetics of [ 3 H]acetylcholine transport ( Fig. 5 ; Table I ). Vesicular acetylcholine uptake by wild-type and mutant VAChTs was saturable and significantly greater at all external acetylcholine concentrations than the transport observed by control PC-12 cells. Transport was completely blocked at 4°C or by the proton ionophore carbonyl cyanide p-trifluoromethoxyphenylhydrazone. The wild-type human VAChT exhibited an apparent K m of 1.1 Ϯ 0.1 mM and a V max of 334 Ϯ 29 pmol/min/mg, which are similar to values reported previously (9) . All tested VAChT-specific mutants examined displayed altered affinities for acetylcholine ( Fig. 5 ; Table I ), with K m values of ϳ3 mM (C391Y), 6 mM (A228V), and 8 mM (S252F). The G233F mutation displayed a K m value of ϳ2 mM. Two of these mutations, G233F and A228V, lie in TMD V, S252F is in TMD VI, and C391Y is in TMD X. LineweaverBurke analyses illustrate that the defects in intrinsic activity of two these mutants (A228V and S252F) are primarily K m effects and not V max effects ( Fig. 5 ; Table I ). The modest V max differences in acetylcholine transport in G233F correlate with minor (Ͻ2-fold) differences in vesamicol binding (B max ). Because the C391Y mutant does not bind vesamicol to normalize the V max , both the K m and V max components of this mutant may be altered.
The binding of vesamicol, a specific antagonist of VAChT and ligand for the low affinity acetylcholine binding site, was also measured in stably transfected PC-12 cells and in transiently transfected CV-1 fibroblasts with similar results. The dissociation constant (K d ) for the binding of vesamicol was only affected slightly by A228V, G233F, and S252F substitutions (Table I). Similarly, replacement of these mutated hydrophobic residues with alanine (G233A, S252A, and C391A) did not affect the binding of vesamicol. The ability of acetylcholine to displace [ 3 H]vesamicol binding (IC 50 ϭ ϳ10 mM) was also approximately normal in these mutants (Table II) . On the other hand, the C391Y mutant did not bind vesamicol (Table I) , and acetylcholine transport in membrane preparations from this mutant was not inhibited by vesamicol (Fig. 6) . DISCUSSION The analysis of homozygous point mutations in the VAChT gene of C. elegans is of considerable value in identifying TMDs of VAChT that are involved in vesicular acetylcholine transport. Worms that lack CeVAChT altogether die within a few days, indicating that the transporter is essential for neural function and for survival. The 12 point mutants we examined are not lethal, indicating that the VAChT protein is expressed and that some degree of activity is retained. Six of the mutations are at sites that are conserved among VMATs and VAChT, whereas four are at sites that are unique to VAChT. Two of the mutations (CeG342E and CeG347R) that introduced charged residues in TMDs at sites conserved between VMATs and VAChTs led to reduced levels of CeVAChT protein. This suggests that alteration of these conserved amino acids may impair the general structural stability of this family of transporters. Mutations in amino acids conserved in VAChTs and VMATs that preserve normal levels of expression of VAChT but impair VAChT function (CeE98K, CeG342E, and CeY400N) may alter protein conformation or substrate/H ϩ antiport. For this study, we have focused on the properties of the VAChTspecific mutants because they are more likely to be relevant to the substrate recognition property of VAChT.
All of the examined VAChT-specific mutants of C. elegans express relatively normal amounts of transporter in vivo with a characteristic punctate distribution in nerve terminals, indicative of a synaptic vesicle-enriched protein. Likewise, when stably expressed in PC-12 cells, the VAChT-specific mutants exhibit appropriate targeting to the small cholinergic vesicles. The active acetylcholine transport properties of the corresponding hVAChT mutant proteins have been examined in vitro using transfected PC-12 cells, a well-characterized system for studying the targeting and intrinsic properties of hVAChT (9, 38) . The K m of VAChT for acetylcholine was increased in the four examined mutants G233F (2 mM), C391Y (3 mM), A228V (6 mM), and S252F (8 mM) relative to wild-type (1 mM). These are the first described mutants of VAChT specifically affecting K m for acetylcholine transport; previously described alterations have resulted in either no change in K m or in inactive proteins (16, 17) . The order of behavioral severity of the unc-17 mutants (CeC370Y ϳ CeS211F Ͻ CeA206V Ͻ CeC230F) is identical to the order of reduced affinity of the corresponding hVAChT mutants for acetylcholine. Thus, these results suggest that the biochemical defects in the intrinsic property of VAChT affect the storage and eventual synaptic release of acetylcholine in vivo.
The differences in the initial velocity transport of acetylcholine documented in the VAChT mutants could be a result of defects in the acetylcholine recognition site of an outwardly facing transporter, in the acetylcholine release site of an inwardly facing transporter, in proton exchange, or in other factors that affect conformational changes or facilitate acetyl -FIG. 4 . VAChT-specific mutants retain targeting to cholinergic vesicles. Postnuclear homogenates from PC-12 cells stably expressing hVAChT and the mutants S252F, A228V, G233F, and C391Y were centrifuged through 0.6 -1.6 M sucrose (left panels) or 5-25% glycerol (right panels). Membrane protein was immunoblotted with affinitypurified antibody against hVAChT or p38 (as a control for the presence of synaptic vesicles).
choline transport through the pore. To begin to define the defect in the mutants with more precision, we examined the binding of acetylcholine to VAChT. For a number of transporters, it has been shown that the affinity of substrate to an outwardly facing transporter may be 10-to 100-fold higher than its affinity to an inwardly facing transporter. For example, the affinity of ␣-methylglucose for the internal site of the sodium-glucose co-transporter is low and exhibits a Km that is 100-fold lower than that found for the extracellular site (43) .
Similarly, the affinity of D-aspartate to the outwardly facing glutamate transporter EAAT1 is ϳ10-fold higher than that to the inwardly facing transporter (44) . Substrate displacement studies with specific antagonists suggest that two substrate affinity states also exist in the VMAT/VAChT transporter family. For VMATs, reserpine acts as a specific competitive inhibitor of monoamine transport, and it binds to the outwardly facing transporter after an ATP-induced conformational change (45) (46) (47) (48) (49) (50) . Monoamines competitively inhibit reserpine FIG. 5 . Kinetic analysis of active vesicular acetylcholine transport. A, saturation isotherm of initial acetylcholine (0.05-12.8 mM) uptake velocity by hVAChT (q) and four mutants, S252F (Ⅺ), A228V (E), G233F (‚), and C391Y (ƒ). The uptake of acetylcholine by the endogenous rat VAChT in PC-12 cells was Ͻ5% of the total uptake and was subtracted. Data are from a representative experiment performed in duplicate, and each experiment was repeated 3-10 times. BϪE, Lineweaver-Burke analyses of initial uptake velocities of the mutants S252F, A228V, G233F, and C391Y, respectively.
binding to this site with K d values similar to their transport K m values. On the other hand, tetrabenazine is a potent noncompetitive inhibitor of VMAT2; monoamines competitively inhibit tetrabenazine binding with IC 50 values 10 -100 times higher than the corresponding K m value (46, 47) . For VAChT, a reserpine-like competitive antagonist that can identify the high affinity acetylcholine recognition site does not exist. However, vesamicol acts as a specific noncompetitive inhibitor of vesicular acetylcholine transport with an inhibition constant (K i ) in the nanomolar range, similar to its dissociation constant (K d ) (51) (52) (53) . Acetylcholine can competitively displace the binding of vesamicol with a K i 10 -100 times greater than the K m for acetylcholine transport (20, 54) . Neither tetrabenazine nor vesamicol binding is affected after the conformational changes induced by the presence of ATP, suggesting that they bind to domains remote from the substrate recognition site. However, when the negative charge in TMD XI is abolished (D425N), the ability of acetylcholine to displace vesamicol binding is signicantly reduced, indicating that vesamicol binding overlaps with the low affinity acetylcholine binding site (17) . Three of the hVAChT K m mutants show normal vesamicol binding. Because the high affinity interaction of vesamicol probably involves several contact points with VAChT, this suggests that the change in intrinsic acetylcholine transport activity of these mutants by introduction of a more bulky and hydrophobic side chain in the TMDs is not due to gross protein misfolding. No differences in the affinity of acetylcholine for the vesamicol binding site were observed in the hVAChT K m mutants. These results indicate that the low affinity acetylcholine binding site of VAChT is intact in these mutants and is not involved in the defect in initial velocity kinetics observed. Parsons and coworkers (55) have shown in vesicles isolated from Torpedo electric lobe that vesamicol binding is abolished after treatment with the cysteine-specific reagents p-chloromercuriphenylsulfonate or phenylmercury acetate. Here, we provide evidence that TMD X is important for vesamicol binding because the C391Y mutant, with its change in TMD X, has lost its ability to interact with vesamicol. A direct interaction of vesamicol with Cys-391 is excluded, however, because the C391A mutation resulted in a protein with normal vesamicol binding. Interestingly, others have shown that mutation of Asp-398 in TMD X to glutamate also results in a protein that catalyzes the transport of acetylcholine but fails to bind vesamicol (16) . Together, these results indicate that the vesamicol binding site and the acetylcholine transport recognition site in VAChT are distinct and, furthermore, that an intact vesamicol binding site is not required for acetylcholine transport.
The defect in initial velocity kinetics observed in the mutants in the present study may be due to alteration in the substrate recognition property of VAChT. It has been postulated that the rate of return of an empty VAChT molecule from luminal exposure to the cytoplasm may affect the measured macroscopic K m (27) . However, it is clear, at least for the related VMATs, that the binding affinity of substrate to the transport recognition site (i.e. monoamine displacement of [ 3 H]reserpine binding; microscopic K m ) is identical to the initial velocity transport rate (macroscopic K m ) (45) (46) (47) (48) (49) (50) . One interpretation of our results is that TMDs V and VI of VAChT may be part of a transport recognition site or acetylcholine translocation cavity because two mutations in these TMDs (A228V and S252F) dramatically affect the K m (but not the V max ) of acetylcholine transport. Notably, the introduction of a single methyl group (A228V) in this important region of VAChT causes a 6-fold decrease in the macroscopic K m measured. However, a direct interaction (hydrogen bonding) between the hydroxyl group of Ser-252 in TMD VI and the ester group of acetylcholine is unlikely because the S252A mutation did not affect the initial velocity of acetylcholine transport. An alternative possibility may be that these mutants only affect conformational changes and the rate of transporter cycling during substrate translocation and may not be related to substrate recognition (i.e. microscopic K m ; see Ref. 27) .
Acetylcholine levels are increased in unc-17 mutants (5, 6). Whereas it is difficult to quantitate the size of the cytoplasmic and vesicular pools of acetylcholine in the cholinergic nerve endings of these mutants, it is likely that the elevated acetylcholine levels are primarily cytoplasmic because the intrinsic activity of VAChT is reduced. In Torpedo electric lobe, a model cholinergic system, cytoplasmic acetylcholine levels are estimated to be between 0.2 and 1 mM (53), somewhat nonsaturating given the K m of VAChT (1 mM) for acetylcholine. Increasing the level of cytoplasmic transmitter may lead to more accumulation in synaptic vesicles and enhanced quantal size. We have shown this to be the case in vitro, where the maximal level of vesicular acetylcholine accumulation is directly proportional to the level of free acetylcholine in the medium (9) . Furthermore, enhanced biosynthesis has been shown to increase the size per quanta in various nerve tissue and culture preparations for several transmitter systems including acetylcholine (56 -58) . One would predict, however, that increased cytoplasmic acetylcholine levels in the unc-17 alleles that display reduced affinity for acetylcholine are not sufficient to overcome the deficit in the intrinsic activity of VAChT to fill vesicles with acetylcholine at levels comparable to wild-type.
